A coronavirus vaccine has been successfully tested in humans for the first time and resulted in a rapid immune response, according to medical journal The Lancet.
A group of 108 volunteers took part in China's CanSino Biologics Inc trial, with promising early results showing antibodies against the virus present in a majority of participants.The vaccine will now need to undergo further testing to confirm the treatment can be used to successfully shield humans from Covid-19 infections. "These results represent an important milestone.
The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further